Thyreoidea Ferrum

The dosage of Ferrous Arsenate is not measured in milligrams for oral consumption, as systemic ingestion is toxic. Instead, dosage is defined by the concentration used in diagnostic procedures.

• Diagnostic Patch Testing: The standard concentration for adult diagnostic testing is typically 1.0% Ferrous Arsenate in a petrolatum vehicle. This is applied via a patch (Finn Chamber or similar device) to the upper back. The total amount of active ingredient per patch is usually less than 0.5 mg, which is well below the threshold for systemic toxicity.
• Concentration Ranges: Depending on the patient's history of sensitivity, a clinician may use a serial dilution ranging from 0.01% to 1.0% to identify the threshold of reactivity.

Ferrous Arsenate is generally not approved for use in pediatric populations. The risk of skin irritation and the potential for systemic absorption of arsenic make it unsuitable for children unless the clinical necessity outweighs the risks, and even then, it is only performed under the supervision of a pediatric allergist or toxicologist. In rare cases where testing is required, concentrations are often reduced to 0.1% or lower.

Renal Impairment

While the amount of Ferrous Arsenate absorbed during a patch test is minimal, patients with severe renal impairment (Stage 4 or 5 Chronic Kidney Disease) should be monitored closely. Arsenic is primarily cleared by the kidneys, and any systemic entry could theoretically persist longer in these patients. No specific dose adjustment is defined for topical use, but the number of simultaneous patches may be limited.

Hepatic Impairment

Because the liver is the primary site for arsenic methylation (detoxification), patients with cirrhosis or acute hepatitis may have a reduced capacity to process even trace amounts of the substance. Caution is advised, and testing should be deferred during periods of acute liver injury.

Elderly Patients

Elderly patients often have thinner skin (atrophy), which may increase the rate of absorption and the intensity of the local reaction. Clinicians typically monitor the test site more frequently in patients over the age of 65 to prevent severe localized skin breakdown.

Ferrous Arsenate is administered exclusively by healthcare professionals in a clinical setting.

• Preparation: The skin on the back is cleaned and dried. No topical steroids or moisturizers should be applied to the area for at least 48 hours prior to the test.
• Application: The patch containing Ferrous Arsenate is applied and secured with hypoallergenic tape.
• Duration: The patch must remain in place and kept completely dry for 48 hours. Patients must avoid showering, heavy sweating, or strenuous exercise during this period.
• Removal: After 48 hours, the clinician removes the patch. A preliminary reading is taken, followed by a final reading at 72 to 96 hours to identify delayed reactions.
• Storage: Clinical preparations must be stored in light-resistant containers at controlled room temperatures (20°C to 25°C) to prevent chemical degradation.

In the context of diagnostic testing, a 'missed dose' refers to the premature removal or falling off of the diagnostic patch. If the patch is removed before the 48-hour mark, the test is considered invalid. The patient should contact their doctor immediately to determine if the patch can be reapplied or if the test must be rescheduled for a later date.

Systemic overdose of Ferrous Arsenate is a medical emergency.

• Signs of Acute Toxicity: If ingested, symptoms include severe 'rice-water' diarrhea, abdominal pain, vomiting, a metallic taste in the mouth, and a garlic-like breath odor.
• Chronic Exposure Signs: Skin hyperpigmentation, palmoplantar keratosis (thickening of the skin on palms and soles), and Mees' lines (white lines on the fingernails).
• Emergency Measures: If systemic exposure is suspected, contact a Poison Control Center immediately. Treatment involves stabilization, gastric lavage (if recent ingestion), and chelation therapy with agents such as Dimercaprol (BAL) or Succimer (DMSA).

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to use this substance without medical guidance.

Because Ferrous Arsenate is used as an allergenic extract, the most common side effects are localized to the site of application. These are often the intended results of a diagnostic test but can be uncomfortable for the patient.

• Erythema (Redness): A persistent redness at the site of the patch is common and may last for several days after the patch is removed.
• Pruritus (Itching): Intense itching at the application site is a hallmark of a positive reaction. Patients are advised not to scratch, as this can lead to secondary infection.
• Local Irritation: A non-allergic, irritant reaction may occur, characterized by a burning sensation or mild stinging.

• Vesiculation: The formation of small blisters at the test site. This indicates a strong positive reaction to the allergen.
• Hyperpigmentation: A temporary darkening of the skin where the Ferrous Arsenate was applied, which may take several weeks to fade.
• Papules: Small, raised bumps at the application site that may feel firm to the touch.

• Contact Urticaria: An immediate hive-like reaction that occurs within minutes of application. This requires immediate removal of the patch.
• Lymphangitis: Inflammation of the lymph vessels leading away from the test site, appearing as red streaks.
• Systemic Flare-up: In highly sensitive individuals, a patch test can cause a temporary worsening of dermatitis at distant body sites (the 'excited skin' syndrome).

While rare in a controlled diagnostic setting, serious reactions can occur.

> Warning: Stop the use of any Ferrous Arsenate preparations and call your doctor immediately if you experience any of these:

• Anaphylaxis: Symptoms include swelling of the face, tongue, or throat; difficulty breathing; and a rapid drop in blood pressure.
• Severe Ulceration: Deep skin breakdown or necrosis (tissue death) at the application site.
• Signs of Systemic Arsenic Poisoning: Severe headache, confusion, dizziness, or intense muscle cramping.
• High Fever: Any fever following the application of an allergenic extract may indicate a systemic inflammatory response or secondary infection.

Ferrous Arsenate is not intended for long-term use. However, chronic exposure to arsenic compounds (as seen in environmental or occupational settings) is associated with significant health risks:

• Carcinogenicity: Long-term exposure to arsenic is a known cause of skin, bladder, and lung cancers. According to the International Agency for Research on Cancer (IARC), arsenic and inorganic arsenic compounds are classified as Group 1 carcinogens.
• Neuropathy: Chronic exposure can lead to peripheral neuropathy, characterized by numbness, tingling, and weakness in the hands and feet.
• Dermatological Changes: Chronic arsenicism can cause 'raindrop' pigmentation and extensive keratosis.

While Ferrous Arsenate as a diagnostic extract does not always carry a specific black box warning in the same way as systemic drugs like clozapine, the arsenic component is subject to stringent FDA safety communications regarding its toxic and carcinogenic potential. Clinicians are warned that any systemic absorption of inorganic arsenic poses a risk of developmental toxicity and cancer. No FDA black box warning is currently mandated specifically for the 1% patch test form, but the substance is handled with the highest level of toxicological precaution.

Report any unusual symptoms to your healthcare provider. If you suspect a severe reaction, seek emergency care immediately.

Ferrous Arsenate is a potent chemical agent containing inorganic arsenic. It must never be ingested, inhaled, or applied to large areas of the body. Its use is strictly limited to diagnostic procedures performed by qualified specialists. Patients with a known history of severe arsenic poisoning or those with highly unstable atopic dermatitis should avoid exposure to this substance.

No FDA black box warnings for Ferrous Arsenate in its capacity as a diagnostic allergenic extract are currently listed. However, it is important to note that the FDA maintains general warnings for all arsenic-containing compounds regarding their status as human carcinogens and potent systemic toxins. The risk of secondary malignancy from a single diagnostic patch test is considered negligible, but the substance must be handled according to hazardous material protocols.

• Allergic Reactions / Anaphylaxis Risk: Although rare with patch testing, there is a theoretical risk of systemic allergic reactions. Testing should only be performed in facilities equipped with emergency resuscitation equipment, including epinephrine.
• Infection Risk: Application of patches over active skin infections or open wounds is contraindicated, as this increases the risk of systemic absorption and localized infection (cellulitis).
• Skin Breakdown: In patients with very sensitive or 'hyper-irritable' skin, Ferrous Arsenate can cause severe localized irritation that may mimic an allergic reaction (false positive).
• Carcinogenic Potential: Because inorganic arsenic is a known carcinogen, clinicians must ensure that the exposure is limited to the minimum concentration and duration necessary for diagnosis.

For standard diagnostic use, extensive lab monitoring is typically not required. However, in cases of suspected systemic absorption or high-dose research use, the following may be monitored:

• Urinary Arsenic Levels: The gold standard for assessing recent arsenic exposure. Total arsenic levels in a 24-hour urine collection are most accurate.
• Complete Blood Count (CBC): To check for signs of bone marrow suppression (anemia, leukopenia) which can occur with arsenic exposure.
• Liver Function Tests (LFTs): To monitor for potential hepatotoxicity if systemic entry is suspected.

Ferrous Arsenate does not typically affect the central nervous system in the doses used for diagnostic testing. Patients are generally safe to drive and operate machinery after the application of a patch test, provided they do not feel dizzy or unwell.

There are no known direct interactions between topical Ferrous Arsenate and alcohol. However, alcohol consumption can cause vasodilation (widening of blood vessels), which may intensify the itching and redness at the patch test site. It is advisable to limit alcohol during the 48-to-96-hour testing window to ensure clear results.

There is no 'withdrawal' associated with Ferrous Arsenate, as it is not used chronically. Once the diagnostic test is complete and the patch is removed, the substance is cleaned from the skin. If a severe reaction occurs, the patch should be removed immediately, and the area washed with mild soap and water.

> Important: Discuss all your medical conditions with your healthcare provider before starting Ferrous Arsenate testing.

Ferrous Arsenate should not be used in combination with other potent skin sensitizers or irritants at the same anatomical site.

• Topical Corticosteroids (High Potency): Drugs like Clobetasol or Betamethasone must not be applied to the test site. These drugs suppress the immune response and will cause a false-negative result, rendering the diagnostic test useless. They should be discontinued at least 2 weeks prior to testing.
• Other Arsenic Compounds: Concurrent exposure to other arsenical medications (e.g., Arsenic Trioxide used in leukemia treatment) is a contraindication due to the risk of cumulative toxicity.

• Systemic Immunosuppressants: Medications such as Prednisone, Cyclosporine, or Methotrexate can significantly dampen the delayed-type hypersensitivity reaction required for a patch test. If a patient cannot safely taper these medications, the results of the Ferrous Arsenate test must be interpreted with extreme caution.
• Chelating Agents: If a patient is currently taking Dimercaprol or Succimer for heavy metal poisoning, these agents will bind to the Ferrous Arsenate and prevent it from interacting with the skin's immune cells.

• Iron Supplements: High doses of oral iron may theoretically compete with the ferrous component of the compound for protein binding sites, though the clinical significance of this during a topical patch test is minimal.
• UV Exposure (Phototherapy): Exposure to UV light (sunlight or tanning beds) on the test site can alter the skin's immune environment and should be avoided for 48 hours before and during the test.

• High-Arsenic Foods: Patients undergoing diagnostic testing for arsenic sensitivity should avoid consuming large amounts of seafood (which contains organic arsenic) or rice (which can contain inorganic arsenic) during the testing period, as this may complicate the interpretation of any systemic symptoms.
• Antioxidants: High-dose Vitamin C or Vitamin E supplements may modulate the oxidative stress response triggered by arsenic, potentially softening the localized reaction.

• St. John's Wort: Known to affect the metabolism of various compounds; however, its effect on topical arsenic is unknown.
• Milk Thistle (Silybum marianum): Often used for liver protection, it may theoretically interfere with the body's natural methylation/detoxification of arsenic if systemic absorption occurs.

• Urinary Arsenic Tests: The use of Ferrous Arsenate in a patch test can cause a transient, slight elevation in urinary arsenic levels, which could lead to a false-positive result in an environmental toxicity screening.
• MRI Contrast Agents: There is no known interaction, but the presence of iron (ferrous) in the compound means large-scale application should be avoided immediately before an MRI, though the amount in a single patch is typically too small to cause interference.

For each major interaction, the mechanism typically involves either pharmacodynamic antagonism (suppressing the immune response) or pharmacokinetic interference (chelation or competitive binding). The clinical consequence is usually a loss of diagnostic accuracy rather than increased toxicity. The management strategy is to discontinue interfering medications for an appropriate washout period before testing.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Ferrous Arsenate must NEVER be used in the following circumstances:

1. 1Known Hypersensitivity to Arsenic: If a patient has a documented history of severe allergic reaction or anaphylaxis to any arsenic-containing compound, the risk of a life-threatening reaction is too high.
2. 2Acute Arsenic Poisoning: Using a diagnostic allergen in a patient already suffering from systemic arsenic toxicity would exacerbate the condition.
3. 3Pregnancy: Arsenic is a known teratogen (causes birth defects) and can cross the placenta. Diagnostic testing with arsenical compounds is strictly avoided during pregnancy.
4. 4Severely Damaged Skin: Application to skin that is ulcerated, infected, or burned is contraindicated due to the high risk of rapid systemic absorption.

Conditions requiring careful risk-benefit analysis include:

• Active Generalized Dermatitis: If the patient has a 'flare' of eczema or psoriasis across their entire body, the patch test may be unreadable (the 'Angry Back' syndrome).
• Severe Renal Failure: The reduced ability to clear even trace amounts of absorbed arsenic requires caution.
• Children under 12: Due to the lack of safety data and higher surface-area-to-volume ratio in children.

Patients who react to Ferrous Arsenate may also show cross-sensitivity to:

• Arsenic Trioxide
• Sodium Arsenate
• Lead Arsenate (historical pesticides)
• Other Heavy Metal Salts: In some cases, patients sensitive to arsenic may also react to nickel or cobalt, although the mechanisms are distinct.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Ferrous Arsenate.

Ferrous Arsenate is generally classified as Category X for diagnostic use. Inorganic arsenic is a potent developmental toxin. Studies in animals and epidemiological data in humans have shown that arsenic exposure during pregnancy is associated with an increased risk of spontaneous abortion, stillbirth, and low birth weight. Furthermore, arsenic is a known teratogen that can interfere with neural tube development. Diagnostic patch testing is not an emergency procedure and should always be postponed until after delivery.

It is known that arsenic can pass into breast milk, although the amount absorbed from a single 1% patch test is likely minimal. However, because of the high toxicity of arsenic to the developing infant's nervous system, healthcare providers typically recommend against patch testing with Ferrous Arsenate while breastfeeding. If testing is essential, the mother may be advised to 'pump and dump' for 48-72 hours following the test.

Ferrous Arsenate is not approved for use in infants or young children. The safety and efficacy of this allergenic extract have not been established in patients under the age of 18. Children have thinner skin and a higher risk of systemic absorption. If a child is suspected of having a specific arsenic allergy, specialized pediatric centers may use much lower concentrations (0.01% or less) under strict observation.

Clinical studies of allergenic extracts often do not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. In geriatric patients, skin reactivity may be diminished due to age-related changes in the immune system (immunosenescence), which can lead to false-negative results. Additionally, the risk of localized skin irritation is higher in the elderly due to skin fragility.

In patients with impaired kidney function, the elimination of any absorbed arsenic is slowed. While the systemic dose from a patch test is extremely low, clinicians should exercise caution in patients with a GFR below 30 mL/min. No specific dose adjustment is required, but the number of simultaneous allergen tests should be minimized to reduce the total chemical load.

Arsenic detoxification depends on hepatic methylation. Patients with severe hepatic impairment (Child-Pugh Class C) may be at an increased risk for toxicity if systemic absorption occurs. Testing should be conducted only if the diagnostic information is critical to the patient's care.

> Important: Special populations require individualized medical assessment.

Ferrous Arsenate acts as a diagnostic allergen through a Type IV Hypersensitivity mechanism. The arsenic ions ($As^{5+}$ or $As^{3+}$) function as haptens that bind to endogenous epidermal proteins. This hapten-protein complex is recognized by the immune system as foreign. Upon re-exposure during a patch test, memory T-cells are recruited to the site, releasing cytokines (such as IFN-gamma and IL-2) that cause localized edema, erythema, and vesicle formation.

At a cellular level, the arsenic component of Ferrous Arsenate inhibits the pyruvate dehydrogenase (PDH) enzyme system by binding to the sulfhydryl groups of lipoic acid. This disrupts the Krebs cycle and inhibits cellular ATP production. The ferrous ($Fe^{2+}$) component can participate in the Fenton reaction, generating hydroxyl radicals that cause localized oxidative damage to cell membranes.

The dose-response relationship of Ferrous Arsenate is non-linear and varies significantly between individuals based on their level of prior sensitization. The time to onset for a positive reaction is typically 48 to 72 hours, reflecting the nature of delayed-type hypersensitivity. The duration of the effect (the visible skin reaction) can last from several days to two weeks.

| Parameter | Value |

|---|---|

| Bioavailability | <2% (Topical) |

| Protein Binding | High (to Keratin and Globulins) |

| Half-life | 10 hours (Arsenite), 30 hours (Arsenate) |

| Tmax | 1-2 hours (if systemic) |

| Metabolism | Hepatic Methylation |

| Excretion | Renal 70%, Fecal 30% |

• Molecular Formula: $Fe_3(AsO_4)_2$
• Molecular Weight: 445.37 g/mol
• Solubility: Practically insoluble in water; soluble in dilute mineral acids.
• Structure: An inorganic salt consisting of three ferrous iron ($Fe^{2+}$) cations and two arsenate ($AsO_4^{3-}$) anions. It typically appears as a green or brown amorphous powder in its pure form.

Ferrous Arsenate is categorized within the Allergenic Extracts therapeutic area. It is specifically grouped with other metal salts used in dermatology, such as Nickel Sulfate and Cobalt Chloride, although it is less commonly used than these substances due to the inherent toxicity of arsenic.